Despite its low safety profile, IL-2 became an FDA-approved drug (Proleukin, Novartis; generic name Aldesleukin) for renal cell carcinoma and metastatic melanoma treatment. The gene discussed is IL2; the disease is hereditary clear cell renal cell carcinoma.